Publication
Tocilizumab: is there life beyond anti-TNF blockade?
dc.contributor.author | Alves, JD | |
dc.contributor.author | Marinho, A | |
dc.contributor.author | Serra, M | |
dc.date.accessioned | 2012-04-18T15:24:53Z | |
dc.date.available | 2012-04-18T15:24:53Z | |
dc.date.issued | 2011 | |
dc.description.abstract | Anti-TNF-α therapy has become the most effective biological treatment for rheumatoid arthritis. Despite having changed the prognosis of the disease establishing new targets for treatment strategy, there are several aspects that still remain unmatched. About 30% of the patients with rheumatoid arthritis have a less than satisfactory response to anti-TNF therapy, which has led the way for the pursuit of new targets and approaches to treatment. IL-6 is one of these alternative targets and data from the more recent clinical trials involving tocilizumab (an anti-IL-6 soluble receptor antibody) suggest advantages in relation to some clinical aspects which are not addressed by anti-TNF-α treatment. | por |
dc.identifier.citation | Int J Clin Pract. 2011 Apr;65(4):508-13 | por |
dc.identifier.issn | 1368-5031 | |
dc.identifier.uri | http://hdl.handle.net/10400.10/557 | |
dc.language.iso | eng | por |
dc.publisher | Medicom International | por |
dc.subject | Rheumatoid arthritis | por |
dc.subject | Arterite reumatóide | por |
dc.subject | Tocilizumab | por |
dc.title | Tocilizumab: is there life beyond anti-TNF blockade? | por |
dc.type | journal article | |
dspace.entity.type | Publication | |
oaire.citation.conferencePlace | Esher [England] | por |
oaire.citation.endPage | 513 | por |
oaire.citation.startPage | 508 | por |
oaire.citation.title | International Journal of Clinical Practice | por |
rcaap.rights | restrictedAccess | |
rcaap.type | article | por |
Files
Original bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- Int J Clin Pract. 2011 Apr, 65(4)508-13.pdf
- Size:
- 92.7 KB
- Format:
- Adobe Portable Document Format
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: